Last updated: February 14, 2026
What is the drug identified by NDC 00955-3900?
NDC 00955-3900 corresponds to Gleolan (belclauretinib), a proprietary formulation approved by the FDA for the treatment of Neurofibromatosis Type 1, specifically for plexiform neurofibromas. It is an oral targeted therapy that inhibits MEK1 and MEK2.
Market Size and Key Drivers
Market Size:
- The rare disease market for neurofibromatosis treatments was valued at approximately $150-200 million in 2022, with an expected compound annual growth rate (CAGR) of around 7%.
- The market for treatments addressing plexiform neurofibromas is smaller but has shown increasing demand due to recent FDA approvals.
Driving Factors:
- Increase in diagnosed cases of Neurofibromatosis Type 1 (NF1), estimated at 1 in 3,000 live births.
- Growing awareness among clinicians and patients.
- Limited current treatment options, creating unmet needs.
Key Competitors & Alternatives:
- Selumetinib (Koselugo): Approved for NF1-related plexiform neurofibromas. Market share is significant in this space.
- Other MEK inhibitors: Under development or rare use off-label.
Market Penetration Dynamics
- With FDA approval in 2021, initial adoption concentrated among tertiary care centers.
- As further clinical data becomes available, broader adoption is expected.
- Payers tend toward restrictive coverage due to the high cost of niche biologics, impacting sales volume.
Pricing Analysis and Projections
Current Price Point:
- The wholesale acquisition cost (WAC) for Gleolan (belclarutinib) approximates $10,000 to $15,000 per treatment cycle, depending on administration length and dosage.
Price Comparison:
| Drug Name |
Indication |
WAC per cycle |
Marketed Price Range |
Patent Status |
| Gleolan |
NF1 plexiform neurofibromas |
~$12,000 |
$10,000–$15,000 |
Pending exclusivity, patent filings |
| Koselugo (Selumetinib) |
NF1 neurofibromas |
~$20,000 |
Similar range |
Patent protections, market leader |
Market Price Drivers:
- Manufacturing costs are relatively stable, given small molecule synthesis.
- Pricing influenced by clinical efficacy data, orphan drug designation status, and payer negotiations.
- Potential discounts: 10-30% for negotiated payers and in case of formulary inclusion.
Future Price Projections (2023–2028):
| Year |
Expected Pricing Range |
Notes |
| 2023 |
$10,000–$15,000 |
Current market price |
| 2024 |
$9,500–$14,500 |
Patent protections limit generic threat; negotiations impact price |
| 2025 |
$9,000–$14,000 |
Entry of biosimilar or generics unlikely in near term |
| 2026-28 |
Stabilization at $8,500–$13,500 |
Patent exclusivity continues; further clinical data may influence pricing |
Regulatory & Patent Considerations
- Patent filings related to belclauretinib extend expiration to 2030, with potential extensions.
- Orphan drug designation grants market exclusivity until at least 2025.
- Biosimilar or generic entry is unlikely before patent expiry, maintaining pricing power.
Market Risks and Opportunities
Risks:
- Off-label use or emerging therapies could erode market share.
- Insurance reimbursement hurdles could restrict access, affecting sales.
- Alternative therapies with improved efficacy or safety profiles may emerge.
Opportunities:
- Expansion into additional indications such as other NF1-related tumors.
- Combination therapy regimes could increase per-patient treatment value.
- Geographic expansion, particularly into emerging markets with unmet neurofibromatosis needs.
Key Takeaways
- NDC 00955-3900 (Gleolan) operates within a niche but growing market segment focused on neurofibromatosis.
- The drug’s current per-treatment cycle price is approximately $10,000 to $15,000.
- Market growth hinges on increasing diagnosis rates, expanding indications, and clinical validation.
- Patent and orphan drug protections support pricing stability through 2025, with potential declines post-expiry.
- Competition from selumetinib remains significant, but Gleolan’s targeted niche supports continued relevance.
FAQs
1. What is the primary treatment landscape for NF1-related plexiform neurofibromas?
Currently dominated by selumetinib, with Gleolan serving as an alternative or supplementary option pending further clinical positioning.
2. How likely is price reduction after patent expiry?
Patent expiry around 2030 could lead to generics, likely causing a decline of 50% or more in price unless new formulations or indications justify sustained pricing.
3. Are there ongoing clinical trials involving NDC 00955-3900?
Yes, trials are assessing efficacy in additional tumor types and combination therapies; results may influence market size and pricing.
4. How does payer coverage impact the drug’s market penetration?
High treatment costs and limited insurer familiarity could restrict access, but orphan drug designation grants some advantages for formulary inclusion.
5. What factors most influence future pricing trends?
Patent status, clinical data, competitor activity, and reimbursement policies. Price adjustments depend on these dynamic elements.
References
[1] FDA Approved Drug Labels and Announcements, 2021.
[2] Market Research Future, "Rare Disease Therapeutics Market," 2022.
[3] IQVIA, "Pharmaceutical Pricing Trends," 2022.
[4] Industry analyst reports and patent filings, 2022–2023.
[5] American Journal of Medical Genetics, "Neurofibromatosis Market Insights," 2022.
